Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

OCULAR THERAPEUTIX, INC.

(OCUL)
  Report
Delayed Nasdaq  -  04:00 2022-11-28 pm EST
2.900 USD   -3.97%
11/09Ocular Therapeutix to Participate at Three Upcoming November 2022 Investor Conferences
AQ
11/09Ocular Therapeutix to Participate at Three Upcoming Investor Conferences
AQ
11/08Ocular Therapeutix Q3 Loss Widens, Revenue Drops; Shares Fall Sharply Tuesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Ocular Therapeutix Sees Positive Trial Results for OTX-TKI Wet AMD Treatment

09/27/2022 | 04:34am EST

By Chris Wack


Ocular Therapeutix Inc. said Tuesday it saw positive interim seven-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, its axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration and other retinal diseases.

The biopharmaceutical company said these interim results will allow it to discuss future development plans with the U.S. Food and Drug Administration.

If the talks with the FDA go well, Ocular plans to initiate a Phase 2 clinical trial in the third quarter of 2023.

Interim data from the U.S.-based Phase 1 clinical trial showed that the single OTX-TKI implant was generally well tolerated with a favorable safety profile. There were no drug-related ocular or systemic serious adverse events observed. No subjects dropped out of either arm.

The interim results showed subjects treated with a single OTX-TKI implant demonstrated stable and sustained best corrected visual acuity and central subfield thickness at seven months. These data have not been reviewed by FDA.

The company also plans to follow subjects in the Phase 1 trial at least until their respective one-year anniversaries of initial dosing, in accordance with the clinical trial protocol. Given the potential broad applicability of OTX-TKI to other retina diseases, Ocular also plans to initiate a U.S.-based Phase 1 clinical trial to evaluate OTX-TKI for the treatment of diabetic retinopathy in the first quarter of 2023.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

09-27-22 0634ET

All news about OCULAR THERAPEUTIX, INC.
11/09Ocular Therapeutix to Participate at Three Upcoming November 2022 Investor Conferences
AQ
11/09Ocular Therapeutix to Participate at Three Upcoming Investor Conferences
AQ
11/08Ocular Therapeutix Q3 Loss Widens, Revenue Drops; Shares Fall Sharply Tuesday
MT
11/08Raymond James Adjusts Price Target on Ocular Therapeutix to $14 From $29, Maintains Str..
MT
11/08HC Wainwright Trims Price Target on Ocular Therapeutix to $9 From $10, Maintains Buy Ra..
MT
11/08Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
BU
11/07Transcript : Ocular Therapeutix, Inc., Q3 2022 Earnings Call, Nov 07, 2022
CI
11/07Ocular Therapeutix : Q3 Earnings Snapshot
AQ
11/07OCULAR THERAPEUTIX, INC Management's Discussion and Analysis of Financial Condition an..
AQ
11/07Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
More news
Analyst Recommendations on OCULAR THERAPEUTIX, INC.
More recommendations
Financials (USD)
Sales 2022 50,2 M - -
Net income 2022 -72,7 M - -
Net cash 2022 62,0 M - -
P/E ratio 2022 -2,99x
Yield 2022 -
Capitalization 223 M 223 M -
EV / Sales 2022 3,21x
EV / Sales 2023 2,58x
Nbr of Employees 228
Free-Float 98,8%
Chart OCULAR THERAPEUTIX, INC.
Duration : Period :
Ocular Therapeutix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCULAR THERAPEUTIX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,90 $
Average target price 13,29 $
Spread / Average Target 358%
EPS Revisions
Managers and Directors
Antony Mattessich President, Chief Executive Officer & Director
Donald Notman Chief Financial Officer
Charles M. Warden Chairman
Peter Jarrett Chief Scientific Officer
Rabia Gurses Ozden Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OCULAR THERAPEUTIX, INC.-58.39%233
JOHNSON & JOHNSON3.66%463 391
ELI LILLY AND COMPANY32.23%347 052
ABBVIE INC.17.01%282 189
PFIZER, INC.-16.05%276 231
MERCK & CO., INC.41.51%272 555